Artemotil Attenuates Fibrosis‐Associated Chondrocyte Remodelling in Osteoarthritis in Association With STC1‐Related TGF‐β/SMAD2/3 Signalling
Guang Zhu, Yang Yang, Ye Ma, Gang Wu, Kuanmin Tian, Xiaoxin He, Rui Wang, Penggang Ma, Zhiqun Tang, Qunhua Jin · 2026
Read Artemotil Attenuates Fibrosis‐Associated Chondrocyte Remodelling in Osteoarthritis in Association With STC1‐Related TGF‐β/SMAD2/3 Signalling by Guang Zhu, Yang Yang, Ye Ma, Gang Wu, Kuanmin Tian, Xiaoxin He, Rui Wang, Penggang Ma, Zhiqun Tang, Qunhua Jin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13580662.txt.
Description
Guang Zhu and co-authors test a drug against cartilage scarring in joint disease, in work published in 2026. Scarring reshapes the joint matrix and speeds wear in osteoarthritis. A protein called STC1 rose in diseased cartilage and tracked with stronger scar signals. The team probed its role in mouse cells, a mouse joint model, and human samples.
Raising STC1 pushed cells toward a scar-like state and fired a known growth pathway. The drug artemotil eased scar and wear signs in cells and in the mouse model, with lower STC1 and calmer pathway action. Restoring STC1 partly undid the drug's gains. The authors name the linked pathway as a drug target.
Catalog record
| CREATOR | Guang Zhu, Yang Yang, Ye Ma, Gang Wu, Kuanmin Tian, Xiaoxin He, Rui Wang, Penggang Ma, Zhiqun Tang, Qunhua Jin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |